News Room
News Room
News Room
Jeff Aronin Named One of the 20 Most Influential Leaders in Healthcare for 2018
Paragon CEO Jeff Aronin Recognized by Insights Care Magazine as “Innovative Entrepreneur Putting Patients First” October 1, 2018 – Paragon Biosciences CEO Jeff Aronin was [...]
Paragon Biosciences Announces Skyline Biosciences as the Newest Addition to Its Growing Portfolio of Companies
CHICAGO – August 21, 2018 – Paragon Biosciences (Paragon) today announced Skyline Biosciences (Skyline) as the newest addition to its growing portfolio of drug-development companies. [...]
Emalex Biosciences Acquires Psyadon Pharmaceuticals to Develop Novel Treatment for Pediatric Tourette Syndrome
CHICAGO – August 14, 2018 – Biopharmaceutical company Emalex Biosciences (Emalex), the newest member of the Paragon Biosciences (Paragon) portfolio of companies, today announced it [...]
Castle Creek Pharmaceuticals Receives FDA Fast Track Designation for Diacerein 1% Ointment for Treatment of Epidermolysis Bullosa Simplex
Biopharmaceutical company currently evaluating diacerein 1% ointment (CCP-020) in ongoing DELIVERS study PARSIPPANY, NJ – August 9, 2018 – Castle Creek Pharmaceuticals, LLC., a US-based [...]
Castle Creek Pharmaceuticals Announces First Patient with Epidermolysis Bullosa Enrolled in Pharmacokinetics Study of Diacerein 1% Ointment
New multi-center Phase 1 study expected to enroll up to 20 people living with rare genetic condition that leads to extremely fragile skin PARSIPPANY, [...]
Castle Creek Pharmaceuticals Receives FDA Rare Pediatric Disease Designation for Diacerein 1% Ointment for Epidermolysis Bullosa
PARSIPPANY, N.J., May 16, 2018 – Castle Creek Pharmaceuticals (CCP), a global company dedicated to delivering transformative therapies to patients with orphan dermatologic and other [...]
